Prelude Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Prelude Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10	Closed	-$2K	–	2133
2020 Q3	$2K	Buy	+10	New	+$3.11K	﹤0.01%	1691
2020 Q1	–	Sell	-46	Closed	-$21K	–	2155
2019 Q4	$21K	Sell	46 -4	-8%	-$1.42K	﹤0.01%	1591
2019 Q3	$15K	Buy	50 +45	+900%	+$14.6K	﹤0.01%	1438
2019 Q2	$2K	Sell	5 -39	-89%	-$13.5K	﹤0.01%	1584
2019 Q1	$18K	Sell	44 -482	-92%	-$193K	﹤0.01%	1335
2018 Q4	$160K	Sell	526 -439	-45%	-$142K	0.01%	802
2018 Q3	$347K	Buy	+965	New	+$330K	0.02%	632
2017 Q4	–	Sell	-97	Closed	-$32K	–	1791
2017 Q3	$32K	Sell	97 -143	-60%	-$39K	﹤0.01%	1221
2017 Q2	$57K	Buy	+240	New	+$54.5K	0.01%	966

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's EIGR Position: Q4 2020 in Review

Prelude Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 10 shares — an estimated $2K sold.

Prelude Capital Management first reported a position in EIGR in Q2 2017 and held it in 9 quarters. The position peaked at $347K in Q3 2018. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Prelude Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 10 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $2K.
Prelude Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2017 and held it in 9 quarters.
Prelude Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $347K in Q3 2018.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.